James F. Lancaster, PhD

home / authors / james-f-lancaster-phd

Articles

June 1st 1998

Safety and Clinical Efficacy of Zileuton in Patients with Chronic Asthma

Stephen C. Lazarus, MD Theodore Lee, MD James P. Kemp, MD Sally Wenzel, MD Louise M. Dube, PhD Rachel F. Ochs, MD, JD Pierre J. Carpentier, MD James F. Lancaster, PhD the Zileuton Study Group

April 1st 1997

Randomized Trial of Zileuton in Patients with Moderate Asthma: Effect of Reduced Dosing Frequency and Amounts on Pulmonary Function and Asthma Symptoms

Lawrence M. DuBuske, MD Jay Grossman, MD Louise M. Dube, PhD Linda J. Swanson, PhD James F. Lancaster, PhD the Zileuton Study Group

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

ICYMI: Highlights From IMS 2024

Published: December 17th 2024 | Updated: December 22nd 2024

ICYMI: Highlights From IMS 2024

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions